Absci, a clinical-stage biotech focused on AI-powered therapeutics, announced a collaboration with Oracle Cloud Infrastructure - OCI and Advanced Micro Devices, Inc. (AMD) to enhance its generative AI Drug Creation Platform.
The partnership enables Absci to consolidate its infrastructure, run large-scale molecular-dynamics simulations, and speed up biologics design cycles.
By selecting OCI as its technical foundation, Absci has accelerated development and operations of its AI workflows, including antibody design. The company is now integrating AMD's Instinct™ MI355X GPUs to further boost performance and scalability.
CEO Sean McClain said the collaboration strengthens Absci's mission to bring new therapeutics to patients faster. Oracle's Dan Spellman highlighted OCI's ability to deliver low-latency, high-throughput infrastructure tailored for Absci's advanced AI workloads.
AMD's Ram Peddibhotla emphasized that combining OCI, AMD EPYC CPUs, and Instinct GPUs provides the performance needed to transform drug discovery and enable faster, more efficient biologics development.
AMD closed at $155.67, down 2.43%, and is trading after hours at $155.79, up 0.08%, on the NasdaqGS.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.